Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826160 · ClinicalTrials.gov registry record
Growth Hormone Dynamics and Cardiac Steatosis in HIV
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 23
- Enrollment target
NCT03826160: Completed study, sponsored by Massachusetts General Hospital.
NCT03826160 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03826160 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Cardiac steatosis is increased among individuals with HIV, and may predispose to cardiac mechanical dysfunction and subsequent heart failure. The pathogenesis and treatment of cardiac steatosis is not well understood. The investigators have previously shown that perturbed growth hormone (GH) secretion in HIV contributes to ectopic fat accumulation in the viscera and the liver. Moreover, the investigators have found that augmentation of endogenous GH secretion with the FDA-approved medication tesamorelin reduces visceral and hepatic fat. In this longitudinal observational study, the investigators will examine patients with HIV and abdominal fat accumulation who either plan or do not plan to initiate tesamorelin prescribed clinically. The investigators hypothesize that blunted GH secretion in HIV is associated with cardiac steatosis. The investigators also hypothesize that use of tesamorelin for 6 months is associated with a reduction in intramyocardial fat and preserved cardiac function.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2022-04-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03826160
The ClinicalTrials.gov registry entry for NCT03826160 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03826160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03826160 about?
NCT03826160 is a clinical study titled "Growth Hormone Dynamics and Cardiac Steatosis in HIV". Cardiac steatosis is increased among individuals with HIV, and may predispose to cardiac mechanical dysfunction and subsequent heart failure. The pathogenesis and treatment of cardiac steatosis is not well understood. The investigators have previously shown that perturbed growth hormone (GH) secreti...
What is the current status of trial NCT03826160?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2019-01-30. Estimated completion is 2022-04-19.
Who is sponsoring clinical trial NCT03826160?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.